- Home
- RXRX vs GENB Comparison
RXRX vs GENB Comparison
Compare RXRX & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXRX | GENB |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RXRX | GENB |
|---|---|---|
| Price | $3.19 | $15.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $7.50 | ★ $23.20 |
| AVG Volume (30 Days) | ★ 21.5M | 875.9K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,681,000.00 | N/A |
| Revenue This Year | $12.11 | N/A |
| Revenue Next Year | $82.52 | $16.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.77 | $11.00 |
| 52 Week High | $7.18 | $16.75 |
Technical Indicators
Market Signals| Indicator | RXRX | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 62.75 |
| Support Level | $2.88 | $11.73 |
| Resistance Level | $4.01 | $16.75 |
| Average True Range (ATR) | 0.26 | 1.14 |
| MACD | -0.02 | 0.24 |
| Stochastic Oscillator | 21.11 | 93.01 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.